Release Details

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

October 25, 2023

Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it will present four posters and one oral presentation at the Society for NeuroOncology (SNO) 28th Annual Meeting being held November 15-19, 2023 in Vancouver, Canada. In addition, the Company plans to host a virtual key opinion leader (KOL) webinar after the conference, featuring Andrew Brenner, MD, PhD (Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio), to discuss new data from the Phase 2 trial of Rhenium-186 Obisbemeda in recurrent glioblastoma (rGBM) that will be presented at SNO.

SNO 28th Annual Meeting – Vancouver Convention Centre

Oral Presentation
Title: Multi-parametric MRI and SPECT Assessment of Treatment Dose and Efficacy in Respect-GBM for recurrent glioblastoma (rGBM)
Presenter: Andrew Brenner, MD, PhD
Date/Time: Saturday, November 18, 2023 at 5:05 pm – 5:10 pm PT
Location: Room 118-120
Posters – Friday, November 17, 2023 at 7:30 pm – 9:30 pm PT in Exhibit Hall A/B
Title: Update Report of the ReSPECT-GBM Phase I/IIa Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma [rGBM] via Convection Enhanced Delivery (CED)
Presenter: Andrew Brenner, MD, PhD
Title: Rhenium-(Re-186)-obisbemeda [Re-186-nanoliposome] (186RNL) Phase 2 for recurrent glioblastoma (rGBM) via Convection Enhance Delivery [CED]
Presenter: Andrew Brenner, MD, PhD
Title: Rhenium (Re-186) obisbemeda{Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2a Dose Escalation Trial: Initial Safety and Feasibility
Presenter: Andrew Brenner, MD, PhD
Title: Efficacy among therapeutically effective absorbed dose patients in ReSPECT-GBM phase I of rhenium-186 nanoliposome (186RNL) in recurrent glioblastoma (rGBM) compared to an external control arm (ECA)
Presenter: Lisa Ensign, PhD

A copy of the presentations will be made available under the Presentations tab of the Investors section of the Company’s website following the meeting at

About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit

Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
(212) 215-2577